MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

Search

AbbVie Inc

Suletud

SektorTervishoid

189.23 -1.23

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

188.52

Max

190.7

Põhinäitajad

By Trading Economics

Sissetulek

1.3B

1.3B

Müük

-1.8B

13B

P/E

Sektori keskmine

81.846

39.857

Aktsiakasum

2.46

Dividenditootlus

3.53

Kasumimarginaal

9.66

Töötajad

55,000

EBITDA

3.2B

3.7B

Soovitused

By TipRanks

Soovitused

Osta

12 kuu keskmine prognoos

+10.83% upside

Dividendid

By Dow Jones

Dividenditootlus

Sektori keskmine

3.53%

2.42%

Järgmine tulemuste avaldamine

31. juuli 2025

Järgmine dividendimakse kuupäev

15. aug 2025

Järgmine aktsia dividendi kuupäev (ex-date)

14. okt 2025

Turustatistika

By TradingEconomics

Turukapital

-5B

338B

Eelmine avamishind

190.46

Eelmine sulgemishind

189.23

Uudiste sentiment

By Acuity

24%

76%

51 / 376 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Weak Bullish Evidence

AbbVie Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

30. juuni 2025, 13:02 UTC

Omandamised, ülevõtmised, äriostud

AbbVie Agrees to Acquire Capstan Therapeutics for $2.1 Billion in Cash

25. apr 2025, 13:57 UTC

Tulu

AbbVie 1Q Revenue Up on Soaring Skyrizi, Rinvoq Sales; Outlook Raised -- Update

25. apr 2025, 12:52 UTC

Tulu

AbbVie 1Q Revenue Up on Soaring Skyrizi, Rinvoq Sales; Outlook Raised

9. apr 2025, 18:18 UTC

Suurimad hinnamuutused turgudel

Pharma Shares Reverse Losses After Tariff Pause

9. apr 2025, 09:39 UTC

Suurimad hinnamuutused turgudel

Pharma Stocks Tumble After Trump Threatens Tariffs on Medicines

30. juuni 2025, 12:47 UTC

Omandamised, ülevõtmised, äriostud

AbbVie Agrees to Acquire Capstan Therapeutics for $2.1B in Cash

30. juuni 2025, 12:33 UTC

Omandamised, ülevõtmised, äriostud

AbbVie Will Acquire Capstan, Including CPTX2309, a Potential First-In-Class in Vivo tLNP anti-CD19 CAR-T Therapy Candidate >ABBV

30. juuni 2025, 12:33 UTC

Omandamised, ülevõtmised, äriostud

AbbVie : Proposed Acquisition Strengthens Commitment to Transforming Patient Care With Capstan's Innovative tLNP Platform Technology >ABBV

30. juuni 2025, 12:32 UTC

Omandamised, ülevõtmised, äriostud

AbbVie Will Pay Up to $2.1B in Cash at Closing to Acquire Capstan >ABBV

30. juuni 2025, 12:31 UTC

Omandamised, ülevõtmised, äriostud

AbbVie To Acquire Capstan Therapeutics, Further Strengthening Commitment To Transforming Patient Care In Immunology >ABBV

7. mai 2025, 09:30 UTC

Peamised uudised

Trump Is Threatening Big Pharma With Tariffs. Tax Changes Might Work Better. -- Heard on the Street -- WSJ

28. apr 2025, 12:44 UTC

Tulu

AbbVie Stock Rises Despite Risks as Earnings Beat Forecasts -- Barrons.com

28. apr 2025, 09:33 UTC

Tulu

AbbVie Stock Rises Despite Risks as Earnings Beat Forecasts -- Barrons.com

25. apr 2025, 16:03 UTC

Tulu

AbbVie Stock Rises Despite Risks as Earnings Beat Forecasts -- Barrons.com

25. apr 2025, 14:00 UTC

Peamised uudised
Tulu

AbbVie Stock Rises as Earnings Beat, Guidance Raised. But Tariffs Could Bite Yet. -- Barrons.com

25. apr 2025, 12:24 UTC

Peamised uudised
Tulu

AbbVie Stock Jumps as Earnings Beat, Guidance Raised. But Tariffs Could Bite Yet. -- Barrons.com

25. apr 2025, 12:03 UTC

Peamised uudised
Tulu

AbbVie Stock Rises as Earnings Beat, Guidance Raised. But Tariffs Could Bite Yet. -- Barrons.com

25. apr 2025, 11:43 UTC

Tulu

AbbVie 1Q U.S. HUMIRA Rev $744M >ABBV

25. apr 2025, 11:43 UTC

Tulu

AbbVie 1Q International HUMIRA Rev $377M >ABBV

25. apr 2025, 11:43 UTC

Tulu

AbbVie 1Q Global Skyrizi Rev $3.43B >ABBV

25. apr 2025, 11:43 UTC

Tulu

AbbVie 1Q Net $1.29B >ABBV

25. apr 2025, 11:43 UTC

Tulu

AbbVie 1Q Global Net Rev From Oncology Portfolio $1.63B >ABBV

25. apr 2025, 11:43 UTC

Tulu

AbbVie 1Q Global IMBRUVICA Rev $738M >ABBV

25. apr 2025, 11:43 UTC

Tulu

AbbVie 1Q EPS 72c >ABBV

25. apr 2025, 11:43 UTC

Tulu

AbbVie 1Q Adj EPS $2.46 >ABBV

25. apr 2025, 11:43 UTC

Tulu

AbbVie 1Q Rev $13.34B >ABBV

25. apr 2025, 11:43 UTC

Tulu

AbbVie Sees FY Adj EPS $12.09-Adj EPS $12.29 >ABBV

14. märts 2025, 09:30 UTC

Peamised uudised

Big Pharma Walked Away From Mental Health. Why Some Are Coming Back. -- Heard on the Street -- WSJ

3. märts 2025, 15:04 UTC

Omandamised, ülevõtmised, äriostud

AbbVie Enters The Obesity Arena. Why It's Paying Up To $2.23 Billion. -- IBD

28. veebr 2025, 12:00 UTC

Peamised uudised

Drug Stocks Are the New Safe Bet in a Shaky Market -- Heard on the Street -- WSJ

Võrdlus sarnastega

Hinnamuutus

AbbVie Inc Prognoos

Hinnasiht

By TipRanks

10.83% tõus

12 kuu keskmine prognoos

Keskmine 212.13 USD  10.83%

Kõrge 250 USD

Madal 170 USD

Põhineb 18 Wall Streeti analüütiku instrumendi AbbVie Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

18 ratings

12

Osta

6

Hoia

0

Müü

Tehniline skoor

By Trading Central

180.37 / 195.54Toetus ja vastupanu

Lühikene perspektiiv

Weak Bullish Evidence

Keskpikk perspektiiv

Bearish Evidence

Pikk perspektiiv

Bearish Evidence

Sentiment

By Acuity

51 / 376 Pingereas Tervishoid

Uudiste sentiment

Väga tugevad tõusu märgid

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Alla keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest AbbVie Inc

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; Janssen Biotech, Inc.; Evolveimmune Therapeutics, Inc.; Genentech, Inc.; AbCellera Biologics Inc.; and Tentarix Biotherapeutics, LP. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.